Drugs / MK-3415
MK-3415
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01513239 | Feb 2012 → May 2015 | Clostridium difficile colitis | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT01241552 | Oct 2011 → Dec 2014 | Clostridium difficile colitis | Merck Sharp & Dohme LLC | Completed | Mixed |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-3415 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01241552 ↗ |
| Known as | actoxumab | “Actoxumab and bezlotoxumab are human monoclonal antibodies against C. difficile toxins A and B, respectively.” PMID 28121498 ↗ Jan 2017 |
| Known as | MDX-066 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109312 ↗ |
| Modality | Monoclonal antibody | “Actoxumab and bezlotoxumab are human monoclonal antibodies against C. difficile toxins A and B, respectively.” PMID 28121498 ↗ Jan 2017 |
| Route | Intravenous | “Single intravenous (IV) infusion of 10 mg/kg MK-3415” NCT01241552 ↗ |